Nutraplus India has commenced commercial production in its new plant at Tarapur for anti-malarial drug LUMEFANTRINE. Previously company was engaged in the manufacturing of Intermediate of the same drug (i.e. n-2 stage) at its existing factory and was selling to the various pharma companies.
Now company is manufacturing the final end product (i.e. LUMEFANTRINE) on full fledge basis at company's new production facilities. The company has obtained necessary approvals and has commenced the commercial production of LUMEFANTRINE. This is a forward integration and shall result in better margin. The company expects to achieving full production capacities in next 3 month in its plant.
Nutraplus India was incorporated as a private limited company in February 1990. The company’s manufacturing unit was commissioned to make APIs and intermediates.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: